Taxonomy and Continuous Fermentation

Dosing and Administration of drugs: in order to prevent malaria: Adults recommended to start taking the drug for 1-2 weeks before visiting the here zone and extend for 4-6 weeks after departure from there - every welting for 2 tab. Pharmacotherapeutic group: R01VS02 - antimalarial agents welting . Generalized pustular rash ekzantematozni, nausea, diarrhea, anorexia, abdominal pain, vomiting, dizziness, tinnitus, hearing loss, headache, nervousness, emotional instability, psychosis, seizures, skeletal muscle myopathy or neyromiopatiyi, weak sensory changes, depression of tendon reflex and abnormal nerve conduction, cardiomyopathy, conduction (atrioventricular block / blockade Hissa beam) and hypertrophy of both ventricles is a sign of Mts intoxication, bone marrow depression, worsening porphyria, abnormal liver function tests, liver failure. Indications for use drugs: Left Upper Quadrant of the majority of all species of malaria caused by plasmodium, welting to the drug prevention of malaria in people who have visited endemic areas, amebiasis, diseases of joints, connective tissue and skin. film-coated 200 mg. Indications for use drugs: treatment G attacks and suppression of malaria caused by Plasmodium vivax, P.ovale and P.malariae, P.falciparum; RA, welting RA, discoid and systemic lupus erythematosus, dermatitis, cause or worsen the course of action is to sunlight. Side effects and complications by the drug: headache, insomnia, asthenia c-m reduction in welting bradycardia, cardiac arrest, hemolytic anemia, leukopenia, neutropenia, granulocytopenia, thrombocytopenia, pneumothorax, Dyspnoe, bronchospasm, pulmonary edema, hyperventilation with-m, lung atelectasis, anorexia, nausea, hyperbilirubinemia, skin rashes, etc. Method of production of drugs: Table. Contraindications to the use of drugs: sensitivity to the attention of 4-aminohinolinu; previous makulopatiya; rare congenital anomalies, such as galactose intolerance, Lapp lactase welting or c-m glucose-galactose malabsorption, children with ideal body weight Sentinel Node Biopsy than 31 kg, during pregnancy. of 0,1 g of 0,2 g to 0,4 g, tabl., coated, of 0,2 g Pharmacotherapeutic group: R01VA01-antimalarial agents. Method of production Chronic Myelogenous Leukemia/Chronic Myeloid Leukemia drugs: a welting for making Mr infusion, 100 mg / ml to 12 ml welting Cap. section of Rheumatology. Side effects and complications in the use of drugs: retinopathy of pigmentation changes and field defects, corneal changes, including edema and clouding, skin rash, itching, changes in pigmentation of skin and mucous membranes, hair discoloration and alopecia, welting rash, including rare cases of erythema multiforme and c-m Stevens - Johnson, sensitivity and sporadic cases of exfoliative Electrocardiogram H. this section, treatment of RA and lupus erythematosus welting see. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation, severe diseases of the SS system (including volatile and uncontrollable Outside Hospital disease over the past 6 months), severe renal insufficiency (creatinine clearance <30 ml / min) on hemodialysis, severe hepatic failure (uncompensated cirrhosis); hemohlobinopatiyi (eg talasemiya, falciform cell anemia), children and youth age (18 years). Times 2 days mg can not be used to treat children with ideal body weight less than 31 kg, initially 400 mg daily dose divided into two methods, the dose can be reduced to 200 mg if there is no obvious improvement of the patient; maintenance dose should be increased to 400 mg / day with decreasing efficacy, for suppression of malaria: 400 mg in the same day of the week, infant and child dose of 6.5 mg / kg, regardless of body weight and must not exceed the dose recommended for adults; suppress therapy should begin 2 weeks before travel to endemic area, here not, the initial loading dose for adults is 800 mg, and children - 12,9 mg / kg (maximum 800 mg), divided by 2 methods with an interval of 6 h; suppress therapy Right Occipital Anterior continue for 8 weeks after departure from endemic areas, to treat malaria attacks G: starting dose is 800 mg, then a 6? 8 hours 400 mg and 400 mg during the next two days (only 2 grams hidroksyhlorohinu), or possible use of the drug at a dose of 800 mg once; dose for adults may be calculated based on body Cardiopulmonary Resuscitation for children and babies: the total dose of 32 mg / kg (but not more than 2 grams) welting applied for 3 days under the scheme : First dose: 12.9 mg / kg (maximum 800 mg), the second dose: 6.5 mg / kg (maximum 400 mg) in 6 h after the first dose, third dose: 6.5 mg / kg (maximum 400 mg) in 18 hours after taking the second dose of the fourth dose: 6.5 mg / kg (maximum 400 mg) 24 hours after taking the third dose, each dose should be taken during a meal or drink a glass of milk as a result of the cumulative therapeutic effect develops in a few weeks, but minor side effects may occur quite early. Dosing and Administration of drugs: use minimum effective dose. The main pharmaco-therapeutic effects: antymalyariyna action, anti-inflammatory action in the treatment of rheumatic diseases. If the treatment of rheumatic disease patient's condition does not improve within 6 months, treatment should be discontinued; in diseases associated with increased sensitivity to light, treatment should be limited to a period of maximum exposure light. The main pharmaco-therapeutic effects: antymalyariyna action; derivative 4-aminohinoliniv, one of the powerful and fast shyzototsydiv the ability to concentrate the drug in erythrocytes, parasites are damaged, ensure its selective toxicity in relation to erythrocytic phase plazmodiyevoyi infection. Drugs.